2016 Gastrointestinal Cancers Symposium
Press Program to Feature New Treatment Strategies, Novel Therapies

For immediate release
December 18, 2015
Contact
Alise Fisher
571-483-1354
alise.fisher@asco.org

ALEXANDRIA, Va. – Co-sponsors of the 2016 Gastrointestinal Cancers Symposium announced today three abstracts that will be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Tuesday, January 19, from 12:00 noon – 1:30 PM (ET).

The following studies will be featured during the presscast:

- A phase III randomized controlled trial evaluating a novel radiolabeled hormone therapy for the treatment of midgut neuroendocrine tumors (Abstract 194).
- A subgroup analysis from a phase III trial investigating everolimus for the treatment of neuroendocrine tumors of the gastrointestinal tract and unknown primary (Abstract 315).
- Results from a phase III trial exploring neoadjuvant chemoradiation for rectal cancer (Abstract 489).

The 2016 Gastrointestinal Cancers Symposium will take place January 21-23 at the Moscone West Building in San Francisco, California. Abstracts presented at the Symposium will discuss the latest science in cancers of the pancreas, small bowel, and hepatobiliary tract; colon and rectum; and esophagus and stomach. On-site facilities for reporters will include a working newsroom and access to leading experts in gastrointestinal cancers.

Visit the 2016 Gastrointestinal Cancers Symposium Media Resource Center for instructions on how to register for the meeting, as well as how to participate in the presscast.
Four leading medical specialty societies co-sponsor the Symposium: the American Gastroenterological Association (AGA) Institute, the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Surgical Oncology (SSO).

**About ASCO:**

Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With nearly 40,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit [www.asco.org](http://www.asco.org). Patient-oriented cancer information is available at [www.cancer.net](http://www.cancer.net).